Study: NCT01820936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1: PCI-32765
Description: Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1: PCI-32765
Description: Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1: PCI-32765
Description: Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1: PCI-32765
Description: Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2: PCI-32765
Description: Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2: PCI-32765
Description: Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2: PCI-32765
Description: Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2: PCI-32765
Description: Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3: PCI-32765
Description: Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3: PCI-32765
Description: Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3: PCI-32765
Description: Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3: PCI-32765
Description: Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4: PCI-32765
Description: Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4: PCI-32765
Description: Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4: PCI-32765
Description: Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4: PCI-32765
Description: Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5: PCI-32765
Description: After completion of the 4-way crossover, an additional separate cohort of 8 subjects were enrolled. These subjects participated in 1 treatment period to document safety and PK